secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profusa, Inc. (PFSA)
CIK:        0001859807
Form:       8-K
Filed at:   2026-05-26T15:05:14+00:00
Accession:  0001213900-26-060879
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profusa and Bio Insights amend asset purchase agreement; delete provision for 12% management share issuance
--------------------------------------------------------------------------------

- Amendment removes Section 4.6 requiring issuance of 12% fully diluted shares to CEO and CFO as retention.
- $30M purchase price for PanOmics multi-omics assay know-how, paid in Series A Convertible Preferred, unchanged.
- Amendment confirms no other changes to the Asset Purchase Agreement remain in full force.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859807/000121390026060879/0001213900-26-060879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859807/000121390026060879/ea0292151-8k_profusa.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-060879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer